Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 8;11:2673–2683. doi: 10.2147/OTT.S159913

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Liu et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

SOX2⁺ cells within the tumors of U251 from different groups. Immunohistochemistry was conducted using SOX2 to determine the percentage of glioblastoma stem-like cells (GSCs) in the tumor xenografts of U87 cells. (A) Histological specimens show fewer GSCs in IT bevacizumab (BEV)-treated tumors than inuntreated or IV BEV-treated specimens. Scale bar, 50 μm. (B) Statistical analysis of the percentage of SOX2⁺ cells within the tumors. Animals that received IT BEV had fewer SOX2⁺ cells in the tumors than those that were untreated or treated with IV BEV. The final outcome was calculated as a ratio (SOX2 positive cells/all cells in a field).

Notes: Data are represented as mean ± SD (n=10), **p<0.01.

Abbreviations: IT, intratumoral; IV, intravenousl; BEV, bevacizumab.